BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma
Metrics: HTML 1177 views | ?
Ying-Ying Li1,2, Chunjing Wu3, Shu-Mei Chen4,5, Sumedh S. Shah6, Medhi Wangpaichitr3,7, Lynn G. Feun2, Macus T. Kuo8, Miguel Suarez9, Jeffrey Prince6, Niramol Savaraj2,3
1Sheila and David Fuente Graduate Program in Cancer Biology, University of Miami Miller School of Medicine, Miami, Florida, USA
2Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA
3Division of Hematology and Oncology, Miami Veterans Affairs Healthcare System, Miami, Florida, USA
4Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan
5Department of Neurosurgery, Taipei Medical University-Wan Fang Hospital, Taipei, Taiwan
6Dauer Electron Microscopy Laboratory, Department of Biology, University of Miami, Miami, FL, USA
7Department of Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA
8Department of Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
9Department of Laboratory Medicine, Miami Veterans Affairs Healthcare System, Miami, Florida, USA
Niramol Savaraj, email: email@example.com
Keywords: BRAF inhibitor resistance, arginine deprivation, autophagy, ASS1 re-expression, ubiquitin-proteasome machinery
Received: September 28, 2015 Accepted: January 03, 2016 Published: January 11, 2016
BRAF inhibitor (BRAFi) has been used for treatment of melanomas harboring V600E mutation. Despite a high initial response rate, resistance to BRAFi is inevitable. Here, we demonstrate that BRAFi-resistant (BR) melanomas are susceptible to arginine deprivation due to inability to initiate re-expression of argininosuccinate synthetase (ASS1, a key enzyme for arginine synthesis) as well as ineffective autophagy. Autophagy and ASS1 re-expression are known to protect melanoma cells from cell death upon arginine deprivation. When melanoma cells become BR cells by long-term in vitro incubation with BRAFi, c-Myc-mediated ASS1 re-expression and the levels of autophagy-associated proteins (AMPK-α1 and Atg5) are attenuated. Furthermore, our study uncovers that downregulation of deubiquitinase USP28 which results in more active c-Myc degradation via ubiquitin-proteasome machinery is the primary mechanism for inability to re-express ASS1 upon arginine deprivation in BR cells. Overexpression of USP28 in BR cells enhances c-Myc expression and hence increases ASS1 transcription upon arginine deprivation, and consequently leads to cell survival. On the other hand, overexpression of Atg5 or AMPK-α1 in BR cells can redirect arginine deprivation-induced apoptosis toward autophagy. The xenograft models also confirm that BR tumors possess lower expression of ASS1 and are hypersensitive to arginine deprivation. These biochemical changes in BRAFi resistance which make them vulnerable to arginine deprivation can be exploited for the future treatment of BR melanoma patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.